CCM
GILD icon

Cinctive Capital Management’s Gilead Sciences GILD Stock Holding History

Cinctive Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-70,000
Closed -$4.16M – 551
2022
Q1 		$4.16M Buy
+70,000
New +$4.47M 0.15% 219

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cinctive Capital Management's GILD Position: Q3 2025 in Review

Cinctive Capital Management sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 17,420 shares — an estimated $1.93M sold.

Cinctive Capital Management first reported a position in GILD in Q4 2019 and held it in 7 quarters. The position peaked at $15.5M in Q3 2024. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

  • Cinctive Capital Management reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
  • Cinctive Capital Management sold 17,420 Gilead Sciences shares in Q3 2025, an estimated $1.93M.
  • Cinctive Capital Management first reported a position in Gilead Sciences in Q4 2019 and held it in 7 quarters.
  • Cinctive Capital Management's Gilead Sciences position peaked at $15.5M in Q3 2024.
  • 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Cinctive Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.